The situation
Scientia Vascular had developed a novel neurovascular access platform and was entering a rapidly evolving competitive landscape. As new technologies emerged and incumbents repositioned, leadership needed the company's commercial story to support long-term category relevance—not just near-term momentum.
The challenge wasn't awareness or design execution.
It was determining how the company should show up, and keep showing up, as the category evolved.
The partnership
RŌG Health served as Scientia Vascular's strategic and creative partner for five years, ultimately as its agency of record.
In practice, that meant we were in the room for the commercial decisions that mattered—positioning, narrative, buyer logic, and how the company presented itself to surgeons, hospital systems, channel partners, and investors. Effectively everything commercially visible, we built: the messaging, the brand materials, the website, the market-facing presence that carried the company's story into the world.
This wasn't a single engagement. It was a sustained partnership through the years a company spends proving it deserves to win its category.
What the work focused on
Rather than starting with execution, the work started with clarity—then carried that clarity all the way through to what the market actually saw.
- The company's true point of distinction in the context of emerging competitors
- A narrative hierarchy that could adapt across buyer contexts without losing coherence
- Guardrails for messaging as the product portfolio and market footprint expanded
- The commercial materials and market presence that brought that narrative to life consistently, over years, across every channel
The result was a coherent commercial face—one that stayed defensible as the company scaled, raised, and drew the attention of strategic acquirers.
The outcome
In 2026, Scientia Vascular was acquired by Medtronic for more than $500 million.
A great product is why an acquirer comes to the table. But what a market sees—the story, the positioning, the commercial presence—is part of what makes a company legible and credible to that acquirer. For five years, that commercial face was ours to build and protect.
We don't claim credit for the science. We do take pride in having been the commercial partner through the chapter that ended in one of neurovascular's notable exits.
Why this matters for RŌG Health today
Partnerships like Scientia Vascular are where the RŌG point of view was formed. Years of sitting beside leadership through high-stakes commercial decisions—what holds up, what breaks, what a company must get right before it scales or sells—is exactly the experience the RŌG diagnostics were later built to distill.
Scientia got that judgment as an embedded partner. The diagnostics make the same judgment available as a focused, structured engagement.